Third Circuit Rules Drug Manufacturer 340B Contract Pharmacy Restrictions Are Legal
The U.S. Court of Appeals for the Third Circuit unanimously ruled that manufacturer restrictions on 340B contract pharmacy access are lawful and HRSA’s policy prohibiting them is unlawful. 18 manufacturers now restrict contract pharmacy access.
Devastating for FQHCs without in-house pharmacies who rely on contract pharmacy arrangements for 340B savings. Combined with the rebate pilot court-ordered pause and expanded audit requirements, 340B contract pharmacy revenue faces pressure from three directions.
Primary source
Bass Berry & SimsFQHC Talent. (2026, January 30). Third Circuit Rules Drug Manufacturer 340B Contract Pharmacy Restrictions Are Legal. Primary source: Bass Berry & Sims. Retrieved June 12, 2026, from https://www.fqhctalent.com/intel/third-circuit-340b-contract-pharmacy-restrictions-legal
More in Risk & Compliance
Jul 5
Section 1557 Language Access Annual Notice Year 1 Anniversary — July 5, 2026 Compliance Window
Jun 9
FTCA CY2027 redeeming applications due June 26 — miss it and your FQHC has a malpractice-coverage gap
Jun 1
Two Compliance Signals for FQHCs: HRSA's FY2026 340B Manufacturer-Audit Results Go Live, and OCR's Ransomware Settlements Preview a Tougher HIPAA Security Rule
Jun 1
Eli Lilly Gives ~50 Covered Entities Five Days to Hand Over 340B Claims Data — or Lose Their Discounts